Integrative systems biology approaches in asthma pharmacogenomics

Pharmacogenomics

Volumn 13, Issue 12, 2012, Pages 1387-1404

  Dahlin, Amber ^a   Tantisira, Kelan G ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

asthma; genes; GWAS; network medicine; pharmacogenomics; SNP; systems biology

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; DEXAMETHASONE; FORMOTEROL; GLUCOCORTICOID; MONTELUKAST; PLACEBO; PRANLUKAST; PREDNISOLONE; SALBUTAMOL; SALMETEROL; ZAFIRLUKAST; ZILEUTON;

ASTHMA; BAYESIAN LEARNING; CLINICAL EFFECTIVENESS; DISEASE CONTROL; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE FUNCTION; GENE INTERACTION; GENE LOCUS; GENE REGULATORY NETWORK; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HUMAN; PHARMACOGENOMICS; PHENOTYPIC VARIATION; PROTEIN INTERACTION; RANDOM FOREST; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMS BIOLOGY; TREATMENT DURATION; TREATMENT PLANNING;

ANIMALS; ASTHMA; HUMANS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; SYSTEMS BIOLOGY;

EID: 84866460152     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.126     Document Type: Review

References (127)

1. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br. Med. Bull. 56(4), 1054-1070 (2000
2. Holloway JW, Arshad SH, Holgate ST. Using genetics to predict the natural history of asthma? J. Allergy Clin. Immunol. 126(2), 200-209; quiz 210-211 (2010
3. Ober C, Vercelli D. Gene-environment interactions in human disease: Muisance or opportunity? Trends Genet. 27(3), 107-115 (2011
4. Wenzel SE. Asthma phenotypes: The evolution from clinical to molecular approaches. Nat. Med. 18(5), 716-725 (2012
5. Ferreira MA, McRae AF, Medland SE et al. Association between ORMDL3, IL1RL1 and a deletion on chromosome 17q21 with asthma risk in Australia. Eur. J. Hum. Genet. 19(4), 458-464 (2011
6. Sleiman PM, Flory J, Imielinski M et al. Variants of DENND1B associated with asthma in children. N. Engl. J. Med. 362(1), 36-44 (2010
7. Moffatt MF, Gut IG, Demenais F et al. A large-scale, consortium-based genomewide association study of asthma. N. Engl. J. Med. 363(13), 1211-1221 (2010
8. Gudbjartsson DF, Bjornsdottir US, Halapi E et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat. Genet. 41(3), 342-347 (2009
9. Himes BE, Hunninghake GM, Baurley JW et al. Genome-wide association analysis identifies PDE4D as an asthma-susceptibility gene. Am. J. Hum. Genet. 84(5), 581-593 (2009
10. Moffatt MF, Kabesch M, Liang L et al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature 448(7152), 470-473 (2007
11. Hawkins GA, Tantisira K, Meyers DA et al. Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study. Am. J. Respir. Crit. Care Med. 174(10), 1101-1109 (2006
12. Reihsaus E, Innis M, MacIntyre N, Liggett SB. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am. J. Respir. Cell Mol. Biol. 8(3), 334-339 (1993
13. Drysdale CM, McGraw DW, Stack CB et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl Acad. Sci. USA 97(19), 10483-10488 (2000
14. Vonk JM, Postma DS, Maarsingh H, Bruinenberg M, Koppelman GH, Meurs H. Arginase 1 and arginase 2 variations associate with asthma, asthma severity and beta2 agonist and steroid response. Pharmacogenet. Genomics 20(3), 179-186 (2010
15. Duroudier NP, Tulah AS, Sayers I. Leukotriene pathway genetics and pharmacogenetics in allergy. Allergy 64(6), 823-839 (2009
16. Drazen JM, Yandava CN, Dube L et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat. Genet. 22(2), 168-170 (1999
17. Tantisira KG, Lima J, Sylvia J, Klanderman B, Weiss ST. 5-lipoxygenase pharmacogenetics in asthma: overlap with Cys-leukotriene receptor antagonist loci. Pharmacogenet. Genomics 19(3), 244-247 (2009
18. Lima JJ, Zhang S, Grant A et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am. J. Respir. Crit. Care Med. 173(4), 379-385 (2006
19. Klotsman M, York TP, Pillai SG et al. Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet. Genomics 17(3), 189-196 (2007
20. Tantisira KG, Lake S, Silverman ES et al. Corticosteroid pharmacogenetics: Association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum. Mol. Genet. 13(13), 1353-1359 (2004
21. Jin Y, Hu D, Peterson EL et al. Dual-specificity phosphatase 1 as a pharmacogenetic modifier of inhaled steroid response among asthmatic patients. J. Allergy Clin. Immunol. 126(3), 618-625.e1-2 (2010
22. Tantisira KG, Silverman ES, Mariani TJ et al. FCER2: A pharmacogenetic basis for severe exacerbations in children with asthma. J. Allergy Clin. Immunol. 120(6), 1285-1291 (2007
23. Koster ES, Maitland-van der Zee AH, Tavendale R et al. FCER2 T2206C variant associated with chronic symptoms and exacerbations in steroid-treated asthmatic children. Allergy 66(12), 1546-1552 (2011
24. Tantisira KG, Lasky-Su J, Harada M et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N. Engl. J. Med. 365(13), 1173-1183 (2011
25. Moore PE, Ryckman KK, Williams SM, Patel N, Summar ML, Sheller Jr. Genetic variants of GSNOR and ADRB2 influence response to albuterol in African-American children with severe asthma. Pediatr. Pulmonol. 44(7), 649-654 (2009
26. Sampson AP, Siddiqui S, Buchanan D et al. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 55(Suppl. 2), S28-S31 (2000
27. Asano K, Shiomi T, Hasegawa N et al. Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics 12(7), 565-570 (2002
28. Mastalerz L, Nizankowska E, Sanak M et al. Clinical and genetic features underlying the response of patients with bronchial asthma to treatment with a leukotriene receptor antagonist. Eur. J. Clin. Invest. 32(12), 949-955 (2002
29. Whelan GJ, Blake K, Kissoon N et al. Effect of montelukast on time-course of exhaled nitric oxide in asthma: Influence of LTC4 synthase A(-444)C polymorphism. Pediatr. Pulmonol. 36(5), 413-420 (2003
30. Lima JJ. Treatment heterogeneity in asthma: Genetics of response to leukotriene modifiers. Mol. Diagn. Ther. 11(2), 97-104 (2007
31. Ye YM, Lee HY, Kim SH et al. Pharmacogenetic study of the effects of NK2R G231E G>A and TBX21 H33Q C>G polymorphisms on asthma control with inhaled corticosteroid treatment. J. Clin. Pharm. Ther. 34(6), 693-701 (2009
32. Mougey EB, Feng H, Castro M, Irvin CG, Lima JJ. Absorption of montelukast is transporter mediated: A common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet. Genomics 19(2), 129-138 (2009
33. Hawkins GA, Lazarus R, Smith RS et al. The glucocorticoid receptor heterocomplex gene STIP1 is associated with improved lung function in asthmatic subjects treated with inhaled corticosteroids. J. Allergy Clin. Immunol. 123(6), 1376-1383.e7 (2009
34. Eichler EE, Flint J, Gibson G et al. Missing heritability and strategies for finding the underlying causes of complex disease. Nat. Rev. Genet. 11(6), 446-450 (2010
35. Nadeau JH, Dudley AM. Genetics. Systems genetics. Science 331(6020), 1015-1016 (2011
36. Koster ES, Rodin AS, Raaijmakers JA, Maitland-van der Zee AH. Systems biology in pharmacogenomic research: The way to personalized prescribing? Pharmacogenomics 10(6), 971-981 (2009
37. Rodin AS, Gogoshin G, Boerwinkle E. Systems biology data analysis methodology in pharmacogenomics. Pharmacogenomics 12(9), 1349-1360 (2011
38. Wang L. Pharmacogenomics: A systems approach. Wiley Interdiscip. Rev. Syst. Biol. Med. 2(1), 3-22 (2010
39. The Childhood Asthma Management Program (CAMP): Design, rationale, and methods. Childhood Asthma Management Program Research Group. Control. Clin. Trials 20(1), 91-120 (1999
40. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N. Engl. J. Med. 343(15), 1054-1063 (2000
41. Lazarus SC, Boushey HA, Fahy JV et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: A randomized controlled trial. JAMA 285(20), 2583-2593 (2001
42. Lemanske RF Jr, Sorkness CA, Mauger EA et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: A randomized controlled trial. JAMA 285(20), 2594-2603 (2001
43. Bielory L, Picone F, Rabinowitz P et al. Multicentre, randomised, parallel-group study of the efficacy and tolerability of flunisolide administered once daily via AeroChamber in the treatment of mild to moderate asthma. Clin. Drug Investig. 19, 93-101 (2000
44. Peters S, Anthonisen N, Castro M et al. Randomized comparison of strategies for reducing treatment in mild persistent asthma. N. Engl. J. Med. 356, 2027-2039 (2007
45. Van Steen K, McQueen MB, Herbert A et al. Genomic screening and replication using the same data set in family-based association testing. Nat. Genet. 37(7), 683-691 (2005
46. Lange C, Lyon H, DeMeo D, Raby B, Silverman EK, Weiss ST. A new powerful non-parametric two-stage approach for testing multiple phenotypes in family-based association studies. Hum. Hered. 56(1-3), 10-17 (2003
47. Israel E, Chinchilli VM, Ford JG et al. Use of regularly scheduled albuterol treatment in asthma: Genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 364(9444), 1505-1512 (2004
48. Tantisira KG, Hwang ES, Raby BA et al. TBX21: A functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc. Natl Acad. Sci. USA 101(52), 18099-18104 (2004
49. Duan QL, Gaume BR, Hawkins GA et al. Regulatory haplotypes in ARG1 are associated with altered bronchodilator response. Am. J. Respir. Crit. Care Med. 183(4), 449-454 (2011
50. Tse SM, Tantisira K, Weiss ST. The pharmacogenetics and pharmacogenomics of asthma therapy. Pharmacogenomics J. 11(6), 383-392 (2011
51. Tantisira K, Weiss S. The pharmacogenetics of asthma treatment. Curr. Allergy Asthma Rep. 9(1), 10-17 (2009
52. Lima JJ, Blake KV, Tantisira KG, Weiss ST. Pharmacogenetics of asthma. Curr. Opin. Pulm. Med. 15(1), 57-62 (2009
53. Weiss ST, Litonjua AA, Lange C et al. Overview of the pharmacogenetics of asthma treatment. Pharmacogenomics J. 6(5), 311-326 (2006
54. Tantisira KG, Weiss ST. The pharmacogenetics of asthma: An update. Curr. Opin. Mol. Ther. 7(3), 209-217 (2005
55. Chung LP, Waterer G, Thompson PJ. Pharmacogenetics of beta2 adrenergic receptor gene polymorphisms, long-acting beta-agonists and asthma. Clin. Exp. Allergy 41(3), 312-326 (2011
56. Taylor DR, Epton MJ, Kennedy MA et al. Bronchodilator response in relation to beta2-adrenoceptor haplotype in patients with asthma. Am. J. Respir. Crit. Care Med. 172(6), 700-703 (2005
57. Carter-Pokras OD, Gergen PJ. Reported asthma among Puerto Rican, Mexican- American, and Cuban children, 1982 through 1984. Am. J. Public Health 83(4), 580-582 (1993
58. Homa DM, Mannino DM, Lara M. Asthma mortality in U.S. Hispanics of Mexican, Puerto Rican, and Cuban heritage, 1990-1995. Am. J. Respir. Crit. Care Med. 161(2 Pt 1), 504-509 (2000
59. Choudhry S, Ung N, Avila PC et al. Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am. J. Respir. Crit. Care Med. 171(6), 563-570 (2005
60. von Homeyer P, Schwinn DA. Pharmacogenomics of beta-adrenergic receptor physiology and response to beta-blockade. Anesth. Analg. 113(6), 1305-1318 (2011
61. Moore PE. Influence of gene-gene interactions on response to albuterol therapy. Pharmacogenomics 12(1), 1-3 (2011
62. Tantisira KG, Small KM, Litonjua AA, Weiss ST, Liggett SB. Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma: Interaction between beta-agonist and corticosteroid pathways. Hum. Mol. Genet. 14(12), 1671-1677 (2005
63. Kim SH, Ye YM, Lee HY, Sin HJ, Park HS. Combined pharmacogenetic effect of ADCY9 and ADRB2 gene polymorphisms on the bronchodilator response to inhaled combination therapy. J. Clin. Pharm. Ther. 36(3), 399-405 (2011
64. Choudhry S, Que LG, Yang Z et al. GSNO reductase and beta2-adrenergic receptor gene-gene interaction: Bronchodilator responsiveness to albuterol. Pharmacogenet. Genomics 20(6), 351-358 (2010
65. Polonikov AV, Ivanov VP, Solodilova MA, Khoroshaya IV, Kozhuhov MA, Panfilov VI. The relationship between polymorphisms in the glutamate cysteine ligase gene and asthma susceptibility. Respir. Med. 101(11), 2422-2424 (2007
66. Duan QL, Du R, Lasky-Su J et al. A polymorphism in the thyroid hormone receptor gene is associated with bronchodilator response in asthmatics. Pharmacogenomics J. doi:10.1038/tpj.2011.56. (2012) (Epub ahead of print
67. Maarsingh H, Zuidhof AB, Bos IS et al. Arginase inhibition protects against allergen-induced airway obstruction, hyperresponsiveness, and inflammation. Am. J. Respir. Crit. Care Med. 178(6), 565-573 (2008
68. Meurs H, McKay S, Maarsingh H et al. Increased arginase activity underlies allergen-induced deficiency of cNOS-derived nitric oxide and airway hyperresponsiveness. Br. J. Pharmacol. 136(3), 391-398 (2002
69. Duan QL, Tantisira KG. Pharmacogenetics of asthma therapy. Curr. Pharm. Des. 15(32), 3742-3753 (2009
70. Tantisira KG, Drazen JM. Genetics and pharmacogenetics of the leukotriene pathway. J. Allergy Clin. Immunol. 124(3), 422-427 (2009
71. York TP, Vargas-Irwin C, Anderson WH, van den Oord EJ. Asthma pharmacogenetic study using finite mixture models to handle drug-response heterogeneity. Pharmacogenomics 10(5), 753-767 (2009
72. Kotani H, Kishi R, Mouri A et al. Influence of leukotriene pathway polymorphisms on clinical responses to montelukast in Japanese patients with asthma. J. Clin. Pharm. Ther. 37(1), 112-116 (2012
73. Via M, De Giacomo A, Corvol H et al. The role of LTA4H and ALOX5AP genes in the risk for asthma in Latinos. Clin. Exp. Allergy 40(4), 582-589 (2010
74. Tcheurekdjian H, Via M, De Giacomo A et al. ALOX5AP and LTA4H polymorphisms modify augmentation of bronchodilator responsiveness by leukotriene modifiers in Latinos. J. Allergy Clin. Immunol. 126(4), 853-858 (2010
75. Bray PJ, Cotton RG. Variations of the human glucocorticoid receptor gene (NR3C1): Pathological and in vitro mutations and polymorphisms. Hum. Mutat. 21(6), 557-568 (2003
76. Hawkins GA, Amelung PJ, Smith RS et al. Identification of polymorphisms in the human glucocorticoid receptor gene (NR3C1) in a multi-racial asthma case and control screening panel. DNA Seq. 15(3), 167-173 (2004
77. Pietras T, Panek M, Tworek D et al. The Bcl I single nucleotide polymorphism of the human glucocorticoid receptor gene h-GR/NR3C1 promoter in patients with bronchial asthma: Pilot study. Mol. Biol. Rep. 38(6), 3953-3958 (2011
78. Panek M, Pietras T, Antczak A, Gorski P, Kuna P, Szemraj J. The role of functional single nucleotide polymorphisms of the human glucocorticoid receptor gene NR3C1 in Polish patients with bronchial asthma. Mol. Biol. Rep. 39(4), 4749-4757 (2011
79. Sayers I, Hall IP. Pharmacogenetic approaches in the treatment of asthma. Curr. Allergy Asthma Rep. 5(2), 101-108 (2005
80. Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ. An integrative systems biology approach to understanding pulmonary diseases. Chest 137(6), 1410-1416 (2010
81. Mitchell T. Machine Learning. McGraw Hill, Columbus, OH, USA (1997
82. Russel S, Norvig P. Artificial Intelligence: A Modern Approach (2nd Edition). Prentice Hall, NJ, USA (2003
83. Brieman L. Random Forests. Mach. Learn. 45(1), 5-32 (2001
84. Junker B, Schreiber F. Analysis of Biological Networks. John Wiley & Sons, NJ, USA (2008
85. Pearl J. Probabilistic Reasoning in Intelligent Systems: Metworks of Plausible Inference. Morgan Kaufmann Publishers, CA, USA (1988
86. Rodin AS, Boerwinkle E. Mining genetic epidemiology data with Bayesian networks I: Bayesian networks and example application (plasma apoE levels). Bioinformatics 21(15), 3273-3278 (2005
87. Needham CJ, Bradford JR, Bulpitt AJ, Westhead DR. A primer on learning in Bayesian networks for computational biology. PLoS Comput. Biol. 3(8), e129 (2007
88. Sebastiani P, Ramoni M. On the use of Bayesian networks to analyse survey data. Res Off. Statist. 41(1), 53-64 (2001
89. Ramoni M, Sebastiani P. Bayesian methods: Intelligent data analysis. In: Intelligent Data Analysis: An Introduction. Hand DJ, Berthold MR (Eds). Springer, NY, USA, 128-166 (2003
90. Sharma S, Poon A, Himes BE et al. Association of variants in innate immune genes with asthma and eczema. Pediatr. Allergy Immunol. 23(4), 315-323 (2011
91. Himes BE, Dai Y, Kohane IS, Weiss ST, Ramoni MF. Prediction of chronic obstructive pulmonary disease (COPD) in asthma patients using electronic medical records. J. Am. Med. Inform. Assoc. 16(3), 371-379 (2009
92. Sanders DL, Aronsky D. Prospective evaluation of a Bayesian Network for detecting asthma exacerbations in a Pediatric Emergency Department. AMIA. Annu. Symp. Proc. 1085 (2006
93. Sanders DL, Aronsky D. Detecting asthma exacerbations in a pediatric emergency department using a Bayesian network. AMIA. Annu. Symp. Proc. 684-688 (2006
94. Himes BE, Wu AC, Duan QL et al. Predicting response to short-acting bronchodilator medication using Bayesian networks. Pharmacogenomics 10(9), 1393-1412 (2009
95. Rodin AS, Litvinenko A, Klos Ket al. Use of wrapper algorithms coupled with a random forests classifier for variable selection in large-scale genomic association studies. J. Comput. Biol. 16(12), 1705-1718 (2009
96. Goldstein BA, Hubbard AE, Cutler A, Barcellos LF. An application of Random Forests to a genome-wide association dataset: Methodological considerations and new findings. BMC Genet. 11, 49 (2010
97. Nonyane BA, Foulkes AS. Application of two machine learning algorithms to genetic association studies in the presence of covariates. BMC Genet. 9, 71 (2008
98. Sun YV. Multigenic modeling of complex disease by random forests. Adv. Genet. 72, 73-99 (2010
99. Bureau A, Dupuis J, Falls Ket al. Identifying SNPs predictive of phenotype using random forests. Genet. Epidemiol. 28(2), 171-182 (2005
100. De Lobel L, Geurts P, Baele G, Castro-Giner F, Kogevinas M, Van Steen K. A screening methodology based on Random Forests to improve the detection of gene-gene interactions. Eur. J. Hum. Genet. 18(10), 1127-1132 (2010
101. Xu M, Tantisira KG, Wu A et al. Genome Wide Association Study to predict severe asthma exacerbations in children using random forests classifiers. BMC Med. Genet. 12, 90 (2011
102. Weiss ST, Raby BA, Rogers A. Asthma genetics and genomics 2009. Curr. Opin. Genet. Dev. 19(3), 279-282 (2009
103. Sun N, Zhao H. Genomic approaches in dissecting complex biological pathways. Pharmacogenomics 5(2), 163-179 (2004
104. Xu X, Wang L, Ding D. Learning module networks from genome-wide location and expression data. FEBS Lett. 578(3), 297-304 (2004
105. Joshi A, De Smet R, Marchal K, Van de Peer Y, Michoel T. Module networks revisited: Computational assessment and prioritization of model predictions. Bioinformatics 25(4), 490-496 (2009
106. Segal E, Shapira M, Regev A et al. Module networks: Identifying regulatory modules and their condition-specific regulators from gene expression data. Nat. Genet. 34(2), 166-176 (2003
107. Hakonarson H, Bjornsdottir US, Halapi E et al. Profiling of genes expressed in peripheral blood mononuclear cells predicts glucocorticoid sensitivity in asthma patients. Proc. Natl Acad. Sci. USA 102(41), 14789-14794 (2005
108. Novershtern N, Itzhaki Z, Manor O, Friedman N, Kaminski N. A functional and regulatory map of asthma. Am. J. Respir. Cell Mol. Biol. 38(3), 324-336 (2008
109. Anderson GP. Endotyping asthma: Mew insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 372(9643), 1107-1119 (2008
110. Tantisira K, Drazen JM. Pharmacogenetics. In: Respiratory Genetics (Volume 1). Shapiro SJ, Lomas D, Weiss ST, Silverman E (Eds). Hodder Education, London, UK, 191-216 (2005
111. Tamari M, Tomita K, Hirota T. Genome-wide association studies of asthma. Allergol. Int. 60(3), 247-252 (2011
112. Haldar P, Pavord ID, Shaw DE et al. Cluster analysis and clinical asthma phenotypes. Am. J. Respir. Crit. Care Med. 178(3), 218-224 (2008
113. Isozaki A, Shoda T, Mimura S et al. A trial of hierarchical cluster analysis of hospitalized wheezy infants and young children based on clinical factors. Arerugi 60(5), 586-592 (2011
114. Fitzpatrick AM, Teague WG, Meyers DA et al. Heterogeneity of severe asthma in childhood: Confirmation by cluster analysis of children in the National Institutes of Health/ National Heart, Lung, and Blood Institute Severe Asthma Research Program. J. Allergy Clin. Immunol. 127(2), 382-389.e1-13 (2011
115. Weatherall M, Travers J, Shirtcliffe PM et al. Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur. Respir. J. 34(4), 812-818 (2009
116. Inouye M, Silander K, Hamalainen E et al. An immune response network associated with blood lipid levels. PLoS Genet. 6(9), e1001113 (2010
117. Franke L, Jansen RC. eQTL analysis in humans. Methods Mol. Biol. 573, 311-328 (2009
118. Grundberg E, Adoue V, Kwan T et al. Global analysis of the impact of environmental perturbation on cis-regulation of gene expression. PLoS Genet. 7(1), e1001279 (2011
119. Laitinen A, Altraja A, Kampe M, Linden M, Virtanen I, Laitinen LA. Tenascin is increased in airway basement membrane of asthmatics and decreased by an inhaled steroid. Am. J. Respir. Crit. Care Med. 156(3 Pt 1), 951-958 (1997
120. Dixon AL, Liang L, Moffatt MF et al. A genome-wide association study of global gene expression. Nat. Genet. 39(10), 1202-1207 (2007
121. Stranger BE, Nica AC, Forrest MS et al. Population genomics of human gene expression. Nat. Genet. 39(10), 1217-1224 (2007
122. Butte AJ, Tamayo P, Slonim D, Golub TR, Kohane IS. Discovering functional relationships between RNA expression and chemotherapeutic susceptibility using relevance networks. Proc. Natl Acad. Sci. USA 97(22), 12182-12186 (2000
123. Schadt EE. Novel integrative genomics strategies to identify genes for complex traits. Anim. Genet. 37(Suppl. 1), 18-23 (2006
124. Schadt EE, Lamb J, Yang X et al. An integrative genomics approach to infer causal associations between gene expression and disease. Nat. Genet. 37(7), 710-717 (2005
125. Schafer J, Strimmer K. An empirical Bayes approach to inferring large-scale gene association networks. Bioinformatics 21(6), 754-764 (2005
126. Chu JH, Weiss ST, Carey VJ, Raby BA. A graphical model approach for inferring large-scale networks integrating gene expression and genetic polymorphism. BMC Syst. Biol. 3, 55 (2009
127. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: MCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30(1), 207-210 (2002